Design Therapeutics, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
Point72 Asset Management, L.P. and related entities have reported beneficial ownership of 3.8% of Design Therapeutics, Inc. common stock as of June 30, 2026.
NASDAQ
Sirenia Capital Management LP and Alex Silverstein have jointly filed a Schedule 13G, reporting beneficial ownership of 9.5% of Design Therapeutics, Inc. common stock.
NASDAQ
Point72 Asset Management and Steven A. Cohen have reported a 5.1% beneficial ownership stake in Design Therapeutics, Inc.
NASDAQ
Point72 Asset Management and Steven A. Cohen have reported a 4.4% beneficial ownership stake in Design Therapeutics, Inc. as of March 31, 2026.
NASDAQ
Point72 Asset Management, along with Point72 Capital Advisors Inc. and Steven A. Cohen, reported a 5.2% beneficial ownership stake in Design Therapeutics, Inc.
NASDAQ
SCHEDULE 13G/A: Star Irrevocable Trust #1 Discloses 6.9% Stake in Design Therapeutics, Inc. via Amended Schedule 13G Filing
An amended Schedule 13G filing reveals that Star Irrevocable Trust #1 holds a 6.9% beneficial ownership stake in Design Therapeutics, Inc. as of December 31, 2024.
NASDAQ
Light Irrevocable Trust #1, along with Jason Howerton, has filed an amended Schedule 13G disclosing a 6.9% beneficial ownership stake in Design Therapeutics, Inc. as of December 31, 2024.